Dyne Therapeutics Expands Debt Facility to $400M, Borrows $50M Immediately
DYN has more than doubled off its 52-week low of $8.06.
Summary
Dyne Therapeutics expanded its debt facility with Hercules Capital to a total of up to $400 million, immediately drawing an additional $50 million and gaining access to further tranches.
Key Events · Financing and Capital Events · DYN
-
Debt Facility Expanded to $400 Million
The company amended its Loan and Security Agreement, expanding the total debt facility with Hercules Capital to an aggregate of up to $400 million. This includes two new $50 million tranches and a $25 million increase to the final tranche.
-
Immediate $50 Million Borrowing
Dyne Therapeutics immediately borrowed one of the additional loan tranches, receiving $50 million on June 16, 2026. This brings the total outstanding principal under the Loan Agreement to $200 million.
-
Increased Financial Flexibility
The amendment also modified the minimum cash covenant, delaying the initial testing date and reducing the required minimum cash from 60% to 40% of outstanding obligations. An additional $125 million is available subject to milestones, and $75 million is available with lender approval.
-
Non-Dilutive Capital
This financing is debt-based, providing capital without immediate dilution to existing shareholders, which is particularly beneficial following the recent shareholder approval to increase authorized common stock.
Analysis · DYN · Life Sciences
Dyne Therapeutics has significantly bolstered its financial position by expanding its senior secured term loan facility. The immediate borrowing of $50 million, coupled with the potential for an additional $150 million, provides crucial non-dilutive capital. This extends the company's cash runway beyond the previously reported Q1 2028 and offers greater flexibility for its ongoing clinical programs, reducing near-term financing risk.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYN was trading at $18.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.